Antiviral resistance during pandemic influenza: implications for stockpiling and drug use

BMC Infectious Diseases

Table 1 Model parameters and estimations

parameter	description	baseline value	references
1/μ _A	mean infectious period of asymptomatic infection	4.1 days	[3, 6, 7]
1/μ _U	mean infectious period of untreated symptomatic infection	4.1 days	[3, 6, 7]
1/μ _T	mean infectious period of treated symptomatic infection	4.1 days	[3, 6, 7]
d _U	death rate of untreated symptomatic infection	0.002 day^-1	[12, 19]
d _T	death rate of treated symptomatic infection	0.001 day^-1	[12, 19]
d _U,r	death rate of resistant infection (low fitness)	0.0002 day^-1	[12, 19]
d _r,U	death rate of resistant infection (high fitness)	0.0008 day^-1	[12, 19]
δ _A	relative transmissibility of asymptomatic infection	0.142	[6, 7, 19]
δ _T	relative transmissibility of treated symptomatic infection	0.4	[3, 12, 19]
δ _r	relative transmissibility of resistant strain (high fitness)	0.9	[19, 27]
p	probability of developing clinical symptoms	0.67	[6, 7]
α	rate of emergence of de novo resistance	0.018 day^-1	[19, 25]
γ	rate of conversion between resistant mutants	0.0036 day^-1	[19, 25]
q	treatment level	variable

Description of the model parameters with their values obtained from the published literature.

ISSN: 1471-2334